Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many (a) male and (b) female patients who have received a diagnosis of infertility are waiting for fertility treatment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
This information is not collected centrally.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many (a) males and (b) females have an infertility diagnosis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
This information is not collected centrally.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter of 20 November 2024 from the hon. Member for Arundel and South Downs.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department endeavours to meet the cross-Government standard of 20 working days for MP responses.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what metrics his Department plans to use to monitor the UK's progress on (a) developing and (b) supporting clinical trials.
Answered by Andrew Gwynne
The Department publishes a UK Clinical Research Delivery Performance Indicators Report monthly, which is available at the following link:
The metrics of the report include, but are not limited to:
- the proportion of all studies receiving combined regulatory review achieved within 60 days, measured from submission to combined regulatory decision;
- the proportion of commercial contract studies open to recruitment within 60 days of the Health Research Authority’s approval letter, or equivalent process used by the devolved administrations;
- the proportion of commercial contract studies recruiting their first participant within 30 days of the sites opening to recruitment, except where this is not expected in the study milestone plan, for example rare disease studies;
- the proportion of all open studies on track, delivering on time and target; and
- the recruitment to all studies, including all commercial studies.
By monitoring these key performance indicators, the Department is committed to improving clinical trial performance in the United Kingdom.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people admitted to hospital with covid-19 (a) had not received a covid-19 vaccination, (b) had received a single covid-19 vaccination and (c) had received both vaccinations in the most recent period for which figures are available.
Answered by Nadhim Zahawi
The information is not held in the format requested.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to minimise the risk of covid-19 vaccines expiring before they are administered.
Answered by Nadhim Zahawi
Public Health England (PHE) manages vaccine stocks by ‘first expiry first out’. This means that stock with the shortest expiry date is identified against orders and sent to National Health Service sites for administration into patients before longer dated stock. This is a standard process employed across all vaccine stocks managed by PHE for the national immunisation programme.
Asked by: Andrew Griffith (Conservative - Arundel and South Downs)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has commissioned a best practice assessment of countries that are issuing covid-19 vaccinations at the fastest rates.
Answered by Nadhim Zahawi
We are working through multilateral channels, such as the G7 and G20, and with the World Health Organization and international partners, including industry. We are discussing collaborative approaches to supporting vaccine development, manufacturing scale-up, and future distribution to meet both domestic and international needs, including for the world’s poorest countries.